Magnitude of Drug–Drug Interactions in Special Populations

• Published in: Pharmaceutics Vol. 14; no. 4; p. 789
• Main Authors: Bettonte, Sara, Berton, Mattia, Marzolini, Catia
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 04.04.2022; MDPI
• Subjects: Aging; Body mass index; drug interaction; Drug interactions; elderly; Enzymes; Ethnicity; Medical Subject Headings-MeSH; Metabolism; obese; Obesity; Older people; Pharmacokinetics; Physiology; Pregnancy; pregnant women; Review; special populations; pregnant women; drug interaction; elderly; special populations; obese
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics14040789

Drug–drug interactions (DDIs) are one of the most frequent causes of adverse drug reactions or loss of treatment efficacy. The risk of DDIs increases with polypharmacy and is therefore of particular concern in individuals likely to present comorbidities (i.e., elderly or obese individuals). These special populations, and the population of pregnant women, are characterized by physiological changes that can impact drug pharmacokinetics and consequently the magnitude of DDIs. This review compiles existing DDI studies in elderly, obese, and pregnant populations that include a control group without the condition of interest. The impact of physiological changes on the magnitude of DDIs was then analyzed by comparing the exposure of a medication in presence and absence of an interacting drug for the special population relative to the control population. Aging does not alter the magnitude of DDIs as the related physiological changes impact the victim and perpetrator drugs to a similar extent, regardless of their elimination pathway. Conversely, the magnitude of DDIs can be changed in obese individuals or pregnant women, as these conditions impact drugs to different extents depending on their metabolic pathway.